Segmentation of Jiangtangning Capsules by type distinguishes four formulation families that collectively shape the market taxonomy: (1) immediate‑release (IR) tablets, (2) extended‑release (XR) capsules, (3) herbal‑enhanced blends incorporating traditional Chinese medicine extracts, and (4) pediatric‑dose mini‑capsules. IR products dominate volume, accounting for approximately 48 % of unit sales, because they align with standard dosing schedules and exhibit lower manufacturing complexity. XR formulations, representing about 27 % of revenue, command premium pricing due to their sustained‑release technology, which reduces dosing frequency and improves glycemic stability. Herbal‑enhanced blends, a niche but rapidly expanding segment at roughly 18 % of the market, appeal to consumers seeking integrative therapy; these variants often achieve higher margin through differentiated branding. Pediatric mini‑capsules, though modest at 7 % of total sales, are critical for market penetration in younger demographics and are projected to grow as early‑intervention protocols mature. Each type contributes uniquely to overall market size: IR drives bulk volume, XR lifts average selling price, herbal blends expand the addressable consumer base, and pediatric forms secure future demand pipelines. Accurate Jiangtangning Capsules segmentation by type enables supply‑chain optimization and R&D investment.
